Jia Ruan, MD, PhD, on Mantle Cell Lymphoma: Phase II Findings on Acalabrutinib/Lenalidomide/Rituximab
2022 ASH Annual Meeting and Exposition
Jia Ruan, MD, PhD, of Meyer Cancer Center, Weill Cornell Medicine, and NewYork-Presbyterian Hospital, discusses trial results demonstrating that the triple chemotherapy-free combination of acalabrutinib, lenalidomide, and rituximab is well tolerated, highly effective, and produces high rates of minimal residual disease (MRD)-negative complete response as an initial treatment for patients with mantle cell lymphoma, including those with TP53 mutations. Real-time MRD analysis may enable treatment de-escalation during maintenance to minimize toxicity, which warrants further evaluation. An expansion cohort of acalabrutinib/lenalidomide/obinutuzumab is being launched (Abstract 73).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The purpose of the study is to evaluate the safety and efficacy of this triplet combination. This triplet combination is built upon our previous report of doublet, which is lenalidomide plus rituximab. It has shown very high response rate and durability of the response, so we would like to see if the addition of a next-generation BTK inhibitor would continue to improve efficacy meanwhile, also maintain or improve safety profile. The other purpose of the study is to evaluate the minimal residual disease status, which is a molecular response with the next-generation sequencing-based assay platform clonoSEQ to evaluate the quality of the response in a real-time base because there's a previous study that suggests the quality of the response measured by minimal residual disease correlate with progression-free survival. So, therefore, we want to see how our triplet combination would improve the response quality measured by minimal residual disease.
And the last purpose of the study is to see, based on the MRD result, can we adjust our treatment strategy, particularly in terms of its intensity and duration, especially, in those patient who can achieve MRD-negative complete remission. The finding of our study has shown that this triplet combination is well tolerated with the expected side effects profile. In addition, it also seems to be highly effective measured by both the response rate using Lugano criteria, as well as minimal residual disease measured by clonoSEQ technology. So a hundred percent of our patients achieved response on study, and the Lugano complete remission rate was 83% measured by the clonoSEQ minimal residual disease, which we defined the threshold of less than one in a million.
About 50% of our patient achieve MRD-negative remission after 12 cycles of treatment, and 67% achieved molecular remission in peripheral blood after 12 cycles of treatment, and 83% after 24 cycles of treatment on the triplet. In addition, we have also evaluated the possibility and the feasibility of de-escalation of our treatment after 24 cycles of triplet therapy by discontinuing acalabrutinib and lenalidomide for those patients in molecular remission. We're very pleased with our preliminary findings and we hope that the results of the study could further contribute to providing options for a patient who's seeking chemotherapy, free combinations with highly effective biological combinations. Furthermore, we're hoping to explore the feasibility of limiting the chronic use of biological agents, but use MRD as a evaluation point to guide our treatment strategy.
Related Videos
The ASCO Post Staff
Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD, both of the Mayo Clinic, discuss the 20% of patients with follicular lymphoma (FL) who relapse early and experience a poor prognosis. The researchers found that FLs with high levels of IRF4 expression are associated with a suppressive tumor microenvironment, and selective IRF4 silencing restores antilymphoma T-cell immunity. Further investigation is warranted to identify the mechanisms by which IRF4 controls tumor immunity to develop precision therapies for this population (Abstract 70).
The ASCO Post Staff
Francesco Maura, MD, of the University of Miami, Sylvester Comprehensive Cancer Center, discusses his team’s findings in which they defined a comprehensive catalogue of genomic determinants of response to DKRd (carfilzomib, lenalidomide, dexamethasone) in newly diagnosed multiple myeloma. The researchers have identified a number of new genomic alterations that explain resistance to the agents currently used in combination regimens (Abstract 470).
The ASCO Post Staff
Tycel J. Phillips, MD, of the City of Hope National Medical Center, discusses data that showed fixed-duration glofitamab monotherapy induced high and durable complete response rates in patients with mantle cell lymphoma (MCL) who received obinutuzumab pretreatment. This is one of the largest data sets and longest follow-ups reported with a CD20/CD3 bispecific monoclonal antibody for patients with relapsed or refractory MCL (Abstract 74).
The ASCO Post Staff
Abdul Rahman Al Armashi, MD, of Seidman Cancer Center, Case Western University, University Hospitals Cleveland Medical Center, discusses a retrospective analysis, using a CDC database, in one of the largest subgroup-based racial population studies analyzing mortality trends in patients with acute myeloid leukemia (AML). Between 2000 and 2019, AML mortality was the highest in Whites and the lowest in American Indians or Alaska Natives. The highest rate of increase in mortality was seen in Asians or Pacific Islanders. Dr. Al Armashi talks about the many variables that might contribute to these inequalities (Abstract 600).
The ASCO Post Staff
Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discusses preliminary results from the dose-expansion phase of the CC-92480-MM-001 Trial, which showed promising efficacy in patients with relapsed and refractory multiple myeloma, including those with prior BCMA-targeted therapies. Patients in these two groups had an overall response rate of 40% and 50%, respectively. The results support the development of mezigdomide, currently being evaluated in combination with standard therapies in multiple myeloma as part of a large, ongoing phase I/II trial (NCT03989414) and planned phase III studies (Abstract 568).